These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21740082)

  • 1. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
    Liesveld JL; Rosell KE; Bechelli J; Lu C; Messina P; Mulford D; Ifthikharuddin JJ; Jordan CT; Phillips Ii GL
    Cancer Invest; 2011 Aug; 29(7):439-50. PubMed ID: 21740082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
    Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.
    Fang J; Rhyasen G; Bolanos L; Rasch C; Varney M; Wunderlich M; Goyama S; Jansen G; Cloos J; Rigolino C; Cortelezzi A; Mulloy JC; Oliva EN; Cuzzola M; Starczynowski DT
    Blood; 2012 Jul; 120(4):858-67. PubMed ID: 22685174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity and drug interactions of proteasome inhibitor Bortezomib in human high-risk myelodysplastic syndrome cells.
    Huang J; Ding T; Yang M; Liu H; Sun X; Jin J
    Int J Hematol; 2011 Apr; 93(4):482-493. PubMed ID: 21451957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.
    Stapnes C; Døskeland AP; Hatfield K; Ersvaer E; Ryningen A; Lorens JB; Gjertsen BT; Bruserud O
    Br J Haematol; 2007 Mar; 136(6):814-28. PubMed ID: 17341267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
    Hu S; Niu H; Inaba H; Orwick S; Rose C; Panetta JC; Yang S; Pounds S; Fan Y; Calabrese C; Rehg JE; Campana D; Rubnitz JE; Baker SD
    J Natl Cancer Inst; 2011 Jun; 103(11):893-905. PubMed ID: 21487100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line].
    He Y; Yang JM; Wang JM; Zhou H; Lü SQ; Hu XX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):794-8. PubMed ID: 18718063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].
    Cai YX; Meng FY; Sun QX; Fu YB; Li L
    Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):737-40. PubMed ID: 19176009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myelogenous leukemia--microenvironment interactions: role of endothelial cells and proteasome inhibition.
    Liesveld JL; Rosell KE; Lu C; Bechelli J; Phillips G; Lancet JE; Abboud CN
    Hematology; 2005 Dec; 10(6):483-94. PubMed ID: 16321813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
    Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
    Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.
    Wang AH; Wei L; Chen L; Zhao SQ; Wu WL; Shen ZX; Li JM
    Ann Hematol; 2011 Aug; 90(8):917-31. PubMed ID: 21340723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.
    Huang M; Thomas D; Li MX; Feng W; Chan SM; Majeti R; Mitchell BS
    Leukemia; 2013 Oct; 27(10):1970-80. PubMed ID: 23877794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
    Baradari V; Höpfner M; Huether A; Schuppan D; Scherübl H
    World J Gastroenterol; 2007 Sep; 13(33):4458-66. PubMed ID: 17724801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.
    Jung HJ; Chen Z; McCarty N
    Am J Hematol; 2012 Dec; 87(12):1057-64. PubMed ID: 22965904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
    Natarajan-Amé S; Park S; Ades L; Vey N; Guerci-Bresler A; Cahn JY; Etienne G; Bordessoule D; Ravoet C; Legros L; Cheze S; Stamatoullas A; Berger E; Schmidt A; Charbonnier A; Chaury MP; Braun T; Fenaux P; Dreyfus F;
    Br J Haematol; 2012 Jul; 158(2):232-237. PubMed ID: 22571447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.
    Warlick ED; Cao Q; Miller J
    Leukemia; 2013 Aug; 27(8):1789-91. PubMed ID: 23446311
    [No Abstract]   [Full Text] [Related]  

  • 19. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
    Yan H; Wang YC; Li D; Wang Y; Liu W; Wu YL; Chen GQ
    Leukemia; 2007 Jul; 21(7):1488-95. PubMed ID: 17495969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE; Rundall BK; Keller MD; Jones DR
    Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.